Results 31 to 40 of about 3,018,020 (304)

Vaccine platforms for the prevention of Lassa fever

open access: yesImmunology Letters, 2019
Lassa fever is an acute viral haemorrhagic illness caused by Lassa virus (LASV), which is endemic throughout much of West Africa. The virus primarily circulates in the Mastomys natalensis reservoir and is transmitted to humans through contact with infectious rodents or their secretions; human-to-human transmission is documented as well.
Purushotham, J, Lambe, T, Gilbert, S
openaire   +3 more sources

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses

open access: yes, 2008
Out of 98 subjects who had participated in the 2000 JE vaccination campaign, 69 people were enrolled in the tests of 2004 and 2005 for the evaluation of long term immune response of a single dose of live attenuated SA14-14-2 JE vaccine.
오희철
core   +1 more source

The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine [PDF]

open access: yes, 2012
This paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine using discrete choice modeling. We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 2008–2009, selected using purposive ...
Newman, Peter A.   +15 more
core   +1 more source

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case-control study in Nepalese children 5 years after immunization

open access: yes, 2007
In July 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine was administered to children living in the Bardiya, Banke and Kailali districts of Nepal.
오희철, 남정모
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Novel Platforms for the Development of a Universal Influenza Vaccine [PDF]

open access: yesFrontiers in Immunology, 2018
Despite advancements in immunotherapeutic approaches, influenza continues to cause severe illness, particularly among immunocompromised individuals, young children, and elderly adults. Vaccination is the most effective way to reduce rates of morbidity and mortality caused by influenza viruses.
Arun Kumar   +5 more
openaire   +5 more sources

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Selection and characterization of vaccine strain for Enterovirus 71 vaccine development

open access: yes, 2012
[[abstract]]Enterovirus 71 (EV71) has recently emerged as an important neurotropic virus in Asia because effective medications and prophylactic vaccine against EV71 infection are not available.
Chang, JY;Chang, CP;Tsai, HH;Lee, CD;Lian, WC;Ih Jen, S;Sai, IH;Liu, CC;Chou, AH;Lu, YJ;Chen, CY;Lee, PH;Chiang, JR;Chong, PC
core   +1 more source

Prospecting the protein design landscape

open access: yesFEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona   +4 more
wiley   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Home - About - Disclaimer - Privacy